EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion

Edward D. Miller, M.D., Former Chief Executive Officer of Johns Hopkins Medicine and the 13th Dean of Johns Hopkins University School of Medicine, Brings Clinical and Business Leadership Expertise

Yvonne Perlberg, M.A., C.P.A., Former Vice President and General Auditor of Amgen, Inc., Contributes Financial and Regulatory Compliance Expertise

25 Jan, 2016, 08:00 ET from EnGeneIC Ltd.

NEW YORK and SYDNEY, Jan. 25, 2016 /PRNewswire/ -- EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced the appointment of Edward D. Miller, M.D., and Yvonne Perlberg, M.A., C.P.A., to the Company's Board of Directors. Previously, Dr. Miller served as Chief Executive Officer of Johns Hopkins Medicine and the 13th Dean of Johns Hopkins University School of Medicine for 16 years until his retirement in 2012. Ms. Perlberg served as Vice President and General Auditor of Amgen, Inc., the world's largest biotechnology company, from 2004 through 2014.

Jennifer MacDiarmid, PhD, joint CEO and Director of EnGeneIC, stated, "We are honored to welcome Ed and Yvonne to EnGeneIC's Board of Directors during this exciting stage in our Company's growth. Ed's business leadership and clinical experience at Johns Hopkins will benefit the Company as we expand our clinical programs into the United States. Yvonne's significant financial and regulatory compliance expertise will be an important asset as the Company continues to expand its U.S. operations." She continued, "We would also like to extend our heartfelt thanks to the two retiring Board members, Stuart Wardman-Browne and Will DeLaat. Stuart has been a great support for us on the business side right from EnGeneIC's inception, and in more recent years, Will has brought his pharmaceutical experience and wise counsel to the table."

As Chief Executive Officer of Johns Hopkins Medicine and the 13th Dean of Johns Hopkins University School of Medicine, Dr. Miller led massive rebuilding and renovation projects at the East Baltimore medical campus, adding two new state-of-the-art hospitals for adult and pediatric patients, as well as clinical and research buildings for the Sidney Kimmel Comprehensive Cancer Center; the Broadway Research Building; the Anne and Mike Armstrong Medical Educational Building; and the Robert H. and Clarice Smith Building that is part of the Wilmer Eye Institute. Dr. Miller also served on the board of directors of Millennium Pharmaceuticals, a NASDAQ-listed biotechnology company, until it was acquired by Takeda Pharmaceuticals. Dr. Miller received his A.B. from Ohio Wesleyan University and his M.D. from the University of Rochester School of Medicine and Dentistry.

Prior to joining Amgen as Vice President and General Auditor in 2004, Ms. Perlberg served as Corporate Vice President and General Auditor of Hughes Electronics Corporation. While at Hughes Electronics, she received a Presidential appointment under the Clinton administration to serve as the defense industry's representative on the U.S. government's Cost Accounting Standards Board, Office of Management and Budget. Ms. Perlberg also previously served as deputy regional director of the Defense Contract Audit Agency within the U.S. Department of Defense. She received her B.S. in business administration from Indiana University and her M.A. in management and administration from Central Michigan University.

Additionally, she attended the Executive Program in Management at the UCLA Anderson Graduate School of Business.

About EnGeneIC and the EDV™ Nanocell Technology 
EnGeneIC is a clinical stage biopharmaceutical company focused on developing its proprietary bacterially-derived EDV™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only found within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug, siRNA, or miRNA payload at high concentrations, intracellularly. The EDV™ nanocell platform has shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and USA.

For more information, please visit www.engeneic.com

U.S. Investor Contact:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com

U.S. Media Contact:
Tiberend Strategic Advisors, Inc. 
Amy S. Wheeler
+1-646-362-5750
awheeler@tiberend.com

Australia Media Contact:
Felicity Moffatt
+61-418-677701
felicity@mdmedia.net.au

SOURCE EnGeneIC Ltd.



RELATED LINKS

http://www.engeneic.com